Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...

At a $10 million valuation, SEGG Media’s July 2025 acquisition of a 51% controlling stake in DotCom Ventures Inc., which owns Concerts.com and TicketStub.com strategically positioned the Company to ...

Schools in Greece opened their gates on Thursday and millions of pupils and students gathered for the opening ceremony.

Results from the Phase 3 STRIDE-13 trial presented at the 6th ESCMID Conference on VaccinesMerck to share STRIDE-13 results with global regulatory authoritiesRAHWAY, N.J.--(BUSINESS WIRE)--$MRK ...

Title : APG990, a monoclonal antibody targeting OX40L, demonstrates safety and an extended half-life in healthy subjects (P3237) Presenter : Carl Dambkowski, M.D., Chief Medical Officer, Apogee ...

Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini could potentially ...

President John Dramani Mahama held his first presidential media engagement of his second term on Wednesday, September 10, ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. Th ...

Did your pet have an accident? Whether it's an old mess or a new one, these tips from the pros will help you decode how to ...

Let me just acknowledge my president, the president of the GJA, and all of you who are here. Fellow countrymen and women, I pledge to ...

As currently practiced in the United States, targeted violence and terrorism prevention draws more from the research and ...